Quantcast
Last updated on April 17, 2014 at 15:37 EDT

Latest VioQuest Pharmaceuticals Stories

2008-10-24 18:00:43

VioQuest Pharmaceuticals (OTCBB: VOQP) today provided a strategic alternatives review and operations update. As disclosed in the Company's periodic filings with the SEC, VioQuest has an immediate need for additional capital to cover its current obligations and future operating expenses and fund its clinical development programs. Over the past year, VioQuest has undertaken a broad-based and intensive effort to raise capital, find a strategic partner, or sell the Company or its assets...

2008-09-10 09:00:09

VioQuest Pharmaceuticals (OTCBB: VOQP) today announced that it has received a determination from the U.S. Food and Drug Administration (FDA) that Xyfid(TM) (1% uracil topical) is a drug rather than a device and would be regulated with the Center for Drug Evaluation and Research (CDER) as opposed to the Center for Devices and Radiologic Health (CDRH). "Beginning in 2008, we initiated parallel regulatory paths for two separate indications for Xyfid," said Michael D. Becker, president and...

2008-08-27 12:00:27

VioQuest Pharmaceuticals has announced that the US Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta. The patent encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases. VioQuest Pharmaceuticals licensed rights to Lenocta (sodium stibogluconate) from the Cleveland Clinic Foundation and is developing the drug as a protein tyrosine phosphatase inhibitor for a range of...

2008-08-26 09:00:28

VioQuest Pharmaceuticals (OTCBB: VOQP) today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta(TM) (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases. "Based on Lenocta's demonstrated...

2008-07-30 09:01:27

VioQuest Pharmaceuticals (OTCBB: VOQP) announced today that the company's novel Akt inhibitor VQD-002 (triciribine phosphate monohydrate, or TCN-P) has been selected as one of the Top 10 most promising oncology projects in development available for strategic partnering by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries....

2008-07-01 09:01:11

VioQuest Pharmaceuticals (OTCBB: VOQP) today announced the submission of a 510(k) application to the United States Food and Drug Administration (FDA). The application seeks marketing clearance for Xyfid(TM) (1% uracil topical), a topical skin preparation intended to relieve and to manage the burning and itching associated with various dermatoses including atopic dermatitis, irritant contact dermatitis, radiation dermatitis and other dry skin conditions, by maintaining a moist wound and skin...